Jul. 27, 2022
BMS-986120
oral PAR4 antagonist Ph. II completed in thrombosis (discontinued) HTS, potency, and PK opt. J. Med. Chem. Bristol-Myers Squibb, Princeton, NJ
oral PAR4 antagonist Ph. II completed in thrombosis (discontinued) HTS, potency, and PK opt. J. Med. Chem. Bristol-Myers Squibb, Princeton, NJ